<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION SPEAKER</th>
<th>SESSION TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830</td>
<td>XVI iwCLL 2015 Opening Ceremony</td>
<td>Traditional Aboriginal Welcome</td>
</tr>
<tr>
<td></td>
<td>Stephen Mulligan</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>iwCLL 2015 Sydney Workshop Chair and Program Chair</td>
<td>CLL Australian Research Consortium Sydney, Australia</td>
</tr>
<tr>
<td>0850</td>
<td>The Hon. Dame Marie Bashir AD, CVO</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Immediate Past Governor of NSW Immediate Past-Chancellor, University of Sydney Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>0900</td>
<td>Max D. Cooper</td>
<td>The B-cell in its 50th Anniversary Year</td>
</tr>
<tr>
<td></td>
<td>Professor of Pathology and Laboratory Medicine Emory University School of Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>0930</td>
<td>Freda Stevenson</td>
<td>Human B-cell receptor structure and function in CLL</td>
</tr>
<tr>
<td></td>
<td>Professor of Immunology University of Southampton, UK</td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td>Chris Goodnow</td>
<td>B-cell signalling and anergy: corruption of self-tolerance signals by oncogenic mutations</td>
</tr>
<tr>
<td></td>
<td>Deputy Director, Garvan Institute of Medical Research Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>1030</td>
<td>Morning Tea</td>
<td></td>
</tr>
<tr>
<td>1100</td>
<td>Farrukh Awan</td>
<td>Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia</td>
</tr>
<tr>
<td></td>
<td>The Ohio State University Columbus, OH, USA</td>
<td></td>
</tr>
<tr>
<td>1110</td>
<td>Giles Best</td>
<td>Dual inhibition of PIM and PI3-kinase by IBL-202 is effective against CLL cells cultured under conditions that mimic the hypoxic tumour microenvironment</td>
</tr>
<tr>
<td></td>
<td>Royal North Shore Hospital Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>1120</td>
<td>Susan O’Brien</td>
<td>Duvelisib (IPI-145), an Oral Dual Inhibitor of PI3K-δ,γ, is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia</td>
</tr>
<tr>
<td></td>
<td>Associate Director for Clinical Science University of California, USA</td>
<td></td>
</tr>
<tr>
<td>1130</td>
<td>Andrew Zelenetz</td>
<td>A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): subgroup efficacy analyses from the HELIOS trial</td>
</tr>
<tr>
<td></td>
<td>Memorial Sloan-Kettering Cancer Center New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>1140</td>
<td>Graeme Fraser</td>
<td>Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial</td>
</tr>
<tr>
<td></td>
<td>Juravinski Cancer Centre, McMaster University Ontario, Canada</td>
<td></td>
</tr>
<tr>
<td>1150</td>
<td>Elaine Willmore</td>
<td>Novel small molecule IKKα inhibitors inhibit non-canonical NF-κB signaling and survival of primary CLL cells</td>
</tr>
<tr>
<td></td>
<td>Newcastle University Newcastle-upon-Tyne, UK</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td>1300</td>
<td>1345</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>1345</td>
<td>1345</td>
<td>The debate: Will novel targeted agents replace chemotherapy in the management of CLL?</td>
</tr>
<tr>
<td>1345</td>
<td>1345</td>
<td></td>
</tr>
<tr>
<td>1430</td>
<td>1430</td>
<td>Flow Cytometry Symposium – Oral Presentations</td>
</tr>
<tr>
<td>1440</td>
<td>1440</td>
<td></td>
</tr>
<tr>
<td>1450</td>
<td>1450</td>
<td></td>
</tr>
<tr>
<td>1500</td>
<td>1500</td>
<td></td>
</tr>
<tr>
<td>1510</td>
<td>1510</td>
<td>Afternoon Tea</td>
</tr>
<tr>
<td>1540</td>
<td>1540</td>
<td>Celgene Silver Sponsor Symposium</td>
</tr>
<tr>
<td>1540</td>
<td>1540</td>
<td>Exploring the role of the microenvironment in CLL Therapy</td>
</tr>
<tr>
<td>1610</td>
<td>1610</td>
<td>Microenvironment – Oral Presentations</td>
</tr>
<tr>
<td>1620</td>
<td>1620</td>
<td></td>
</tr>
<tr>
<td>1630</td>
<td>1630</td>
<td></td>
</tr>
<tr>
<td>1640</td>
<td>1640</td>
<td></td>
</tr>
<tr>
<td>1650</td>
<td>1650</td>
<td></td>
</tr>
<tr>
<td>1700</td>
<td>1700</td>
<td></td>
</tr>
<tr>
<td>1710</td>
<td>1710</td>
<td>iwCLL 2015 Award Presentations</td>
</tr>
<tr>
<td>1730</td>
<td>1730</td>
<td>Close</td>
</tr>
</tbody>
</table>
### Tuesday 8 September 2015 - Day Two: Patient Related Risk: Biology and Management

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730</td>
<td>Registration</td>
</tr>
<tr>
<td>0800</td>
<td><strong>Novartis Silver Sponsor Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><strong>More Evidence, More Options First-Line Treatment of CLL</strong></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Bryone Kuss</td>
</tr>
<tr>
<td>0830</td>
<td><strong>Epidemiology</strong></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Daniel Catovsky</td>
</tr>
<tr>
<td>0830</td>
<td><strong>Workshop on CLL in Asia – Oral Presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Session Chairs: Jian Yong Li and Ligui Qiu</td>
</tr>
<tr>
<td>0900</td>
<td>Wei Xu</td>
</tr>
<tr>
<td></td>
<td>Jiangsu Province Hospital, Nanjing, China</td>
</tr>
<tr>
<td>0910</td>
<td>Wei Xu</td>
</tr>
<tr>
<td></td>
<td>Jiangsu Province Hospital, Nanjing, China</td>
</tr>
<tr>
<td>0920</td>
<td>Thomas S.Y Chan &amp; Eric Tse</td>
</tr>
<tr>
<td></td>
<td>Queen Mary Hospital, Hong Kong, China</td>
</tr>
<tr>
<td>0930</td>
<td>Colin Phipps &amp; Yuh Shan Lee</td>
</tr>
<tr>
<td></td>
<td>Singapore</td>
</tr>
<tr>
<td>0940</td>
<td>Jun Takizawa</td>
</tr>
<tr>
<td></td>
<td>Niigata University Faculty of Medicine, Niigata, Japan</td>
</tr>
<tr>
<td>0950</td>
<td>Morning Tea</td>
</tr>
<tr>
<td>1020</td>
<td>Stephen Mulligan</td>
</tr>
<tr>
<td></td>
<td>iwCLL 2015 Sydney Workshop Chair and Program Chair</td>
</tr>
<tr>
<td></td>
<td>CLL Australian Research Consortium</td>
</tr>
<tr>
<td></td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>1030</td>
<td>Daniel Catovsky</td>
</tr>
<tr>
<td></td>
<td>The Institute of Cancer Research</td>
</tr>
<tr>
<td></td>
<td>London, UK</td>
</tr>
<tr>
<td>1040</td>
<td>Talha Munir</td>
</tr>
<tr>
<td></td>
<td>St. James's Hospital, Leeds, UK</td>
</tr>
<tr>
<td>1050</td>
<td>Philip Thompson</td>
</tr>
<tr>
<td></td>
<td>M.D. Anderson Cancer Center, Houston, TX, USA</td>
</tr>
<tr>
<td>1100</td>
<td>Francesc Bosch</td>
</tr>
<tr>
<td></td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>1110</td>
<td>Roche Gold Sponsor Symposium</td>
</tr>
<tr>
<td></td>
<td><strong>What is the role of patient fitness in the evolving treatment landscape</strong></td>
</tr>
<tr>
<td></td>
<td>Session Chairs: Constantine Tam and Francesc Bosch</td>
</tr>
<tr>
<td>1111</td>
<td>Valentin Goede</td>
</tr>
<tr>
<td></td>
<td>Hematologist, Oncologist and Gerontologist, University of Cologne, Germany</td>
</tr>
<tr>
<td>1131</td>
<td>Michael Keating</td>
</tr>
<tr>
<td></td>
<td>President of CLL Global Foundation, US, Professor of Medicine, University of Texas, MD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>1146</td>
<td>Michael Hailek</td>
</tr>
<tr>
<td></td>
<td>Principal Investigator, Deputy Scientific Coordinator, University of Cologne, Germany</td>
</tr>
<tr>
<td>1201</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>1210</td>
<td>Lunch</td>
</tr>
<tr>
<td>Time</td>
<td>Session Name</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1310</td>
<td>Manipulating the Immune System in CLL</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>1330</td>
<td></td>
</tr>
<tr>
<td>1350</td>
<td>Manipulating the Immune System in CLL – Oral Presentations</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>1340</td>
<td></td>
</tr>
<tr>
<td>1340</td>
<td></td>
</tr>
<tr>
<td>1340</td>
<td></td>
</tr>
<tr>
<td>1340</td>
<td>Economics of the Novel Therapy Era</td>
</tr>
<tr>
<td>1350</td>
<td></td>
</tr>
<tr>
<td>1350</td>
<td>Janssen Opal Sponsor Symposium</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>1700</td>
<td>Review of iwCLL Best Poster</td>
</tr>
<tr>
<td>1715</td>
<td>Poster Viewing Reception</td>
</tr>
<tr>
<td>1830</td>
<td>Close</td>
</tr>
</tbody>
</table>
## Wednesday 9 September 2015 - Day three: Disease Related Risk: Biology and Management

### Registration

**The Genetics of CLL**

**Session Chairs:** Davide Rossi and Bryone Kuss

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830</td>
<td>Catherine Wu</td>
<td>Medical Oncology, Harvard Medical School Dana-Farber Cancer Institute, USA</td>
<td>Driver Mutations in CLL</td>
</tr>
<tr>
<td>0900</td>
<td>Carlo Croce</td>
<td>Director, Institute of Genetics The Ohio State University, USA</td>
<td>MicroRNA</td>
</tr>
</tbody>
</table>

### Genetics - Oral Presentations

**Session Chairs:** Davide Rossi and Bryone Kuss

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>0920</td>
<td>Lauren Thurgood</td>
<td>Adelaide, Australia</td>
<td>Segregation of CLL patients based on their cytogenetic background reveals marked differences in global protein expression</td>
</tr>
<tr>
<td>0930</td>
<td>Gero Knittel</td>
<td>Cologne, Germany</td>
<td>Establishment of a pre-clinical in vivo platform spanning low-risk to high-risk CLL</td>
</tr>
<tr>
<td>0940</td>
<td>Johnathan Strefford</td>
<td>Southampton, UK</td>
<td>Telomere length predicts progression and overall survival in chronic lymphocytic leukaemia: data from the UK LRF CLL4 trial</td>
</tr>
<tr>
<td>0950</td>
<td>Eva Kimby</td>
<td>Stockholm, Sweden</td>
<td>Targeted sequencing reveals subclonal complexity of CD49d subpopulations in CLL patients</td>
</tr>
</tbody>
</table>

### Morning Tea

**Gilead Silver Sponsor Symposium**

**A new era in the treatment of difficult to treat CLL: addressing the unmet need**

**Session Chair:** Stephen Mulligan

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1040</td>
<td>Stephen Mulligan</td>
<td>iwCLL 2015 Sydney Workshop Chair and Program Chair CLL Australian Research Consortium Sydney, Australia</td>
<td>Introduction: Current CLL treatment in specific patient populations - what is the unmet need?</td>
</tr>
<tr>
<td></td>
<td>Jennifer Brown</td>
<td>Associate Professor, Harvard Medical School Director, CLL Center, Dana-Farber Cancer Institute, USA</td>
<td>Clinical Case Introduction</td>
</tr>
<tr>
<td></td>
<td>Barbara Eichhorst</td>
<td>University of Cologne, Germany</td>
<td>Evolution of treatment options in CLL</td>
</tr>
<tr>
<td></td>
<td>Jennifer Brown</td>
<td>Associate Professor, Harvard Medical School Director, CLL Center, Dana-Farber Cancer Institute, USA</td>
<td>From clinical trials to clinical practice: integrating BCR targeted therapies in CLL treatment</td>
</tr>
</tbody>
</table>

### Summary and Close

**“Real-World” Novel and Other Therapies – Oral Presentations**

**Session Chairs:** Arnon Kater and Andrew Roberts

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1110</td>
<td>Adrian Wiestner</td>
<td>National Heart, Lung, and Blood Institute (NIH) Maryland, USA</td>
<td>Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib</td>
</tr>
<tr>
<td>1120</td>
<td>Paula Cramer</td>
<td>University of Cologne, Germany</td>
<td>ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial</td>
</tr>
<tr>
<td>1130</td>
<td>Florence Cymbalista</td>
<td>Bobigny, France</td>
<td>Atrial fibrillation and Ibrutinib: advocacy for guidelines</td>
</tr>
<tr>
<td>1140</td>
<td>Constantine Tam</td>
<td>Peter MacCallum Cancer Centre Melbourne, Australia</td>
<td>Favorable Patient Survival after Failure of Venetoclax (ABT-199/GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</td>
</tr>
<tr>
<td>1150</td>
<td>Olivier Tourinhac</td>
<td>Clermont-Ferrand, France</td>
<td>RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based</td>
</tr>
</tbody>
</table>

### Lunch
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Authors and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1300</td>
<td><strong>AbbVie Gold Sponsor Symposium</strong></td>
<td><strong>Evaluation of P53 Abnormalities in the Evolving Therapeutic Landscape of Chronic Lymphocytic Leukemia</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Session Chair:</strong> John Seymour</td>
<td>Genetic Aberrations in CLL, Including p53 abnormalities, and their impact on patient outcomes</td>
</tr>
<tr>
<td></td>
<td><strong>Susan O’Brien</strong></td>
<td>Associate Director for Clinical Science, University of California, USA</td>
</tr>
<tr>
<td></td>
<td><strong>Davide Rossi</strong></td>
<td>Assistant Professor of Hematology, Amedeo Avogadro University of Eastern Piedmont, Italy</td>
</tr>
<tr>
<td></td>
<td><strong>John Seymour</strong></td>
<td>Chair of the Haematology Service Peter MacCallum Cancer Center, Melbourne</td>
</tr>
<tr>
<td>1400</td>
<td><strong>Best of iwCLL Symposium – Oral Presentations</strong></td>
<td>Session Chairs: Kanti Rai, Federico Caligaris-Cappio and Stephen Mulligan</td>
</tr>
<tr>
<td></td>
<td><strong>Maria Teresa Sabrina Bertilaccio</strong></td>
<td>San Raffaele Scientific Institute Milan, Italy</td>
</tr>
<tr>
<td></td>
<td><strong>Hien Nguyen</strong></td>
<td>CECAD Research Center Cologne, Germany</td>
</tr>
<tr>
<td></td>
<td><strong>Siddha Kasar</strong></td>
<td>Dana-Farber Cancer Institute Boston, MA, USA</td>
</tr>
<tr>
<td></td>
<td><strong>Xiao-Jie Yan</strong></td>
<td>Feinstein Institute for Medical Research Manhasset, NY, USA</td>
</tr>
<tr>
<td></td>
<td><strong>Emma Young</strong></td>
<td>Uppsala University, Sweden</td>
</tr>
<tr>
<td></td>
<td><strong>Anne-Sophie Michallet</strong></td>
<td>Lyon, France</td>
</tr>
<tr>
<td></td>
<td><strong>Panel discussion, Post Test and Closing Remarks</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Closing Ceremony</strong></td>
<td>Session Chairs: Kanti Rai, Daniel Catovsky, Federico Caligaris-Cappio, Michael Keating, Michael Hallek, Nicholas Chiorazzi, Carlo Croce, Peter Hillmen and Thomas Kipps, Faculty: Kanti Rai, Daniel Catovsky, Federico Caligaris-Cappio, Michael Keating, Michael Hallek, Nicholas Chiorazzi, Carlo Croce, Peter Hillmen and Thomas Kipps, Local Organising Committee: Stephen Mulligan, Giles Best, Bryone Kuss, Xavier Badoux and Devinder Gill</td>
</tr>
<tr>
<td>1330</td>
<td><strong>Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression</strong></td>
<td>Maria Teresa Sabrina Bertilaccio San Raffaele Scientific Institute Milan, Italy</td>
</tr>
<tr>
<td>1410</td>
<td><strong>Functional role of LYN kinase in CLL progression - an in vivo analysis</strong></td>
<td>Hien Nguyen CECAD Research Center Cologne, Germany</td>
</tr>
<tr>
<td>1420</td>
<td><strong>Two Distinct Activation-induced Cytidine Deaminase (Aid) Signatures Identified In The Evolution Of Indolent Chronic Lymphocytic Leukemia Using Whole Genome Sequencing</strong></td>
<td>Siddha Kasar Dana-Farber Cancer Institute Boston, MA, USA</td>
</tr>
<tr>
<td>1430</td>
<td><strong>Over-expression of activation-induced cytidine deaminase in TCL1 mice leads to the development of IGHV-mutated and -unmutated CLL clones that resemble unique subsets of human CLL</strong></td>
<td>Xiao-Jie Yan Feinstein Institute for Medical Research Manhasset, NY, USA</td>
</tr>
<tr>
<td>1440</td>
<td><strong>EGR2 mutations in chronic lymphocytic leukemia- a new bad player?</strong></td>
<td>Emma Young Uppsala University, Sweden</td>
</tr>
<tr>
<td>1450</td>
<td><strong>Rituximab in combination with bendamustine or chlorambucill for the treatment of chronic lymphocytic leukaemia: primary results from the randomised phase ITib MABLE study</strong></td>
<td>Anne-Sophie Michallet Lyon, France</td>
</tr>
<tr>
<td>1500</td>
<td><strong>Evaluation of P53 Abnormalities in the Evolving Therapeutic Landscape of Chronic Lymphocytic Leukemia</strong></td>
<td>Session Chairs: Kanti Rai, Daniel Catovsky, Federico Caligaris-Cappio, Michael Keating, Michael Hallek, Nicholas Chiorazzi, Carlo Croce, Peter Hillmen and Thomas Kipps, Faculty: Kanti Rai, Daniel Catovsky, Federico Caligaris-Cappio, Michael Keating, Michael Hallek, Nicholas Chiorazzi, Carlo Croce, Peter Hillmen and Thomas Kipps, Local Organising Committee: Stephen Mulligan, Giles Best, Bryone Kuss, Xavier Badoux and Devinder Gill</td>
</tr>
<tr>
<td>1530</td>
<td><strong>Workshop Close and Afternoon Tea</strong></td>
<td></td>
</tr>
</tbody>
</table>